New results will be rapidly shared through direct exchanges between the participants and will be disseminated to the entire scientific community through:
- the Annual Meetings and concurrent workshops which might be open, enterily or in part, to external participants.
- participation in specialized courses, international workshops and conferences.
- publication in scientific journals of the highest quality level.
Dissemination activity will take into account the intellectual property policy of the consortium (see next paragraph) in case of patentable results. It is predicted that the ITN will produce knowledge on novel “molecular mechanisms”, “targets” and “drugs” that has the potential for application in the combat against CLD and HCC (therapy). It will be of utmost importance to identify the scientific output that needs to be protected. ITN intellectual properties right (IPR) and the Technology Transfer Offices (TTO) of the participating institutes in the consortium will be responsible for identifying research results that may require protection. An IP protection policy for the Network will be developed according to the published guidelines for IP Protection for FP7 projects (http://cordis.europa.eu/fp7/calls-grantagreement_en.html#standard_ga). IP policy will be agreed upon by the participants at the outset of the ITN and will be implemented in the Consortium Agreement. All ESRs joining the Network will be made aware of the IPR policies ofthe Network and of relevant best practices.